BCWM
ALXN

Bartlett & Co Wealth Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Bartlett & Co Wealth Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-50
Closed -$9.19K – 1093
2021
Q2 		$9.19K Hold
50
– – ﹤0.01% 703
2021
Q1 		$7.65K Hold
50
– – ﹤0.01% 758
2020
Q4 		$7.81K Hold
50
– – ﹤0.01% 757
2020
Q3 		$5.72K Hold
50
– – ﹤0.01% 724
2020
Q2 		$5.61K Hold
50
– – ﹤0.01% 730
2020
Q1 		$4.49K Hold
50
– – ﹤0.01% 732
2019
Q4 		$5.41K Hold
50
– – ﹤0.01% 758
2019
Q3 		$4.9K Hold
50
– – ﹤0.01% 778
2019
Q2 		$6.55K Hold
50
– – ﹤0.01% 615
2019
Q1 		$6.76K Hold
50
– – ﹤0.01% 601
2018
Q4 		$4.87K Hold
50
– – ﹤0.01% 620
2018
Q3 		$6.95K Hold
50
– – ﹤0.01% 621
2018
Q2 		$6.21K Hold
50
– – ﹤0.01% 625
2018
Q1 		$5.57K Buy
+50
New +$5.98K ﹤0.01% 650

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Bartlett & Co Wealth Management's ALXN Position: Q3 2021 in Review

Bartlett & Co Wealth Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 50 shares — an estimated $9.19K sold.

Bartlett & Co Wealth Management first reported a position in ALXN in Q1 2018 and held it in 14 quarters. The position peaked at $9.19K in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Bartlett & Co Wealth Management reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Bartlett & Co Wealth Management sold 50 Alexion Pharmaceuticals shares in Q3 2021, an estimated $9.19K.
  • Bartlett & Co Wealth Management first reported a position in Alexion Pharmaceuticals in Q1 2018 and held it in 14 quarters.
  • Bartlett & Co Wealth Management's Alexion Pharmaceuticals position peaked at $9.19K in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Bartlett & Co Wealth Management's 13F filing for Q3 2021, filed 14 Feb 2024.